← Retour au Screener

Sector: Santé
Open in Terminal → PRLDLive chart · Key metrics · News · Smart money

Prelude Therapeutics

PRLD Small Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

3,77 €
-0.69% aujourd'hui
52W: 0,65 € – 4,83 €
52W Low: 0,65 € Position: 74.5% 52W High: 4,83 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
20.58x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
300 M €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-95.25%
Rentabilité des capitaux propres
Beta
1.01
Sensibilité au marché
Positions vendeuses
6.73%
% du flottant vendu à découvert
Volume moyen
383,919
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
3 analysts
Avg. Price Target
6,98 €
+85.19% upside
Target Range
5,24 € – 8,73 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 79 Exchange: NMS

Prelude Therapeutics en bref

Prelude Therapeutics (PRLD) is currently trading at 3,77 € with a market capitalization of 300 M €. The 52-week range spans from 0,65 € to 4,83 €; the current price is 22% below the yearly high.

💰 Dividende

Prelude Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

3 analystes évaluent Prelude Therapeutics (PRLD) au consensus : Achat Fort. L'objectif de cours moyen est de 6,98 €, soit un potentiel de +85.19% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 5,24 € à 8,73 €.

Prelude Therapeutics : la thèse d'investissement en détail

Prelude Therapeutics (PRLD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 85.19% upside from current levels — analyst sentiment is firmly constructive.

À surveiller

  • The analyst consensus price target implies 85.19% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Marge brute élevée de 100% — signe d'un pouvoir de fixation des prix
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 29.45)
Points faibles
  • Free cash flow négatif

Aperçu technique

MM 50 jours
3,82 €
-1.37% vs. cours
MM 200 jours
2,30 €
+64.26% vs. cours
Sous le plus haut 52s
−22%
4,83 €
Au-dessus du plus bas 52s
+476%
0,65 €

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

Risque de marché (Bêta)
1.01 · Proche du marché
Évolue plus que le marché global
Positions vendeuses
6.73% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
29.45 · Faible
Dette totale / capitaux propres

The data points to market-like volatility, elevated short interest (6.73%).

Trading Data

50-Day MA: 3,82 €
200-Day MA: 2,30 €
Volume: 859,200
Avg. Volume: 383,919
Short Ratio: 3.84
P/B Ratio: 5.93x
Debt/Equity: 29.45x
Free Cash Flow: -15 647 189 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Prelude Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut